Skip to main navigation

Header Nav

Company
Pipeline and Technology
Business Development
Investors
Contact Us

Select Page

Press Releases

Header Nav

Welcome
Financial Information
- IR Snapshot
- Annual Reports
Financial Fundamentals
Stock Information
- Stock Quote & Chart
- Historic Price Lookup
Filings
- SEC Filings
- Ownership
Corporate Governance
Corporate Presentation
Events
Press Releases
Investor Alerts

Toolkit

Email Alerts
Print Page
Share
RSS Feeds
Contact IR
Search

Press Releases

Year

Sep 4, 2024

Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock

Topline data anticipated in late September 2024 WARRINGTON, Pa. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and

Aug 20, 2024

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa. , Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics , Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter

Aug 14, 2024

Windtree Announces New Additions and Changes to Its Board of Directors

WARRINGTON, Pa. , Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced changes to its board of

Jul 25, 2024

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data WARRINGTON, Pa. , July 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on

Jul 22, 2024

Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock

$12.9 Million Transaction Includes Approximately $3.4 Million of New Funding and a $9.5 Million Full Cancellation of Outstanding Senior Notes and Extinguishment of Series B Preferred Shares The Company Also Established a $35 Million Equity Line of Credit WARRINGTON, Pa.

May 7, 2024

Windtree Therapeutics Regains Compliance with Nasdaq

WARRINGTON, Pa. , May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has received a Bid Price

Apr 18, 2024

Windtree Therapeutics Announces Reverse Stock Split

WARRINGTON, Pa. , April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the Company’s Board of Directors has

Apr 17, 2024

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa. , April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter

Apr 8, 2024

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

WARRINGTON, Pa. , April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc.

Feb 1, 2024

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

WARRINGTON, Pa. , Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with Chang

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

YM Twitter Feed